University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Microbiology & Immunology
  • Microbiology & Immunology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Microbiology & Immunology
  • Microbiology & Immunology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Clinical trials for the prevention and treatment ofCOVID-19: current state of play

    Thumbnail
    Citations
    Scopus
    Web of Science
    Altmetric
    8
    5
    Author
    Davis, JS; Ferreira, D; Denholm, JT; Tong, SYC
    Date
    2020-06-27
    Source Title
    Medical Journal of Australia
    Publisher
    WILEY
    University of Melbourne Author/s
    Tong, Steven; Denholm, Justin
    Affiliation
    Microbiology and Immunology
    Doherty Institute
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Davis, J. S., Ferreira, D., Denholm, J. T. & Tong, S. Y. C. (2020). Clinical trials for the prevention and treatment ofCOVID-19: current state of play. MEDICAL JOURNAL OF AUSTRALIA, 213 (2), pp.86-93. https://doi.org/10.5694/mja2.50673.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/254506
    DOI
    10.5694/mja2.50673
    Open Access URL
    https://europepmc.org/articles/PMC7361919?pdf=render
    Abstract
    Since coronavirus disease 2019 (COVID-19) emerged in Wuhan, China in December 2019 and spread around the world, over 1100 clinical studies have been registered globally on clinical trials registries, including over 500 randomised controlled trials. Such rapid development and launch of clinical trials is impressive but presents challenges, including the potential for duplication and competition. There is currently no known effective treatment for COVID-19. In order to focus on those studies most likely to influence clinical practice, we summarise the 31 currently registered randomised trials with a target sample size of at least 1000 participants. We have grouped these trials into four categories: prophylaxis; treatment of outpatients with mild COVID-19; treatment of hospitalised patients with moderate COVID-19; and treatment of hospitalised patients with moderate or severe disease. The most common therapeutic agent being trialled currently is hydroxychloroquine (24 trials with potential sample size of over 25 000 participants), followed by lopinavir-ritonavir (seven trials) and remdesevir (five trials) There are many candidate drugs in pre-clinical and early phase development, and these form a pipeline for future large clinical trials if current candidate therapies prove ineffective or unsafe.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45770]
    • Doherty Institute - Research Publications [371]
    • Microbiology & Immunology - Research Publications [1555]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors